BIRC3 Antibody (N-term)
Affinity Purified Rabbit Polyclonal Antibody (Pab)
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB, IF, IHC-P, E |
---|---|
Primary Accession | Q13489 |
Other Accession | NP_001156.1, NP_892007.1 |
Reactivity | Human |
Host | Rabbit |
Clonality | Polyclonal |
Isotype | Rabbit IgG |
Calculated MW | 68372 Da |
Antigen Region | 59-88 aa |
Gene ID | 330 |
---|---|
Other Names | Baculoviral IAP repeat-containing protein 3, 632-, Apoptosis inhibitor 2, API2, C-IAP2, IAP homolog C, Inhibitor of apoptosis protein 1, IAP-1, hIAP-1, hIAP1, RING finger protein 49, TNFR2-TRAF-signaling complex protein 1, BIRC3, API2, IAP1, MIHC, RNF49 |
Target/Specificity | This BIRC3 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 59-88 amino acids from the N-terminal region of human BIRC3. |
Dilution | IF~~1:10~50 WB~~1:1000 IHC-P~~1:10~50 |
Format | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
Precautions | BIRC3 Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | BIRC3 |
---|---|
Synonyms | API2, MIHC, RNF49 |
Function | Multi-functional protein which regulates not only caspases and apoptosis, but also modulates inflammatory signaling and immunity, mitogenic kinase signaling and cell proliferation, as well as cell invasion and metastasis. Acts as an E3 ubiquitin-protein ligase regulating NF-kappa-B signaling and regulates both canonical and non- canonical NF-kappa-B signaling by acting in opposite directions: acts as a positive regulator of the canonical pathway and suppresses constitutive activation of non-canonical NF-kappa-B signaling. The target proteins for its E3 ubiquitin-protein ligase activity include: RIPK1, RIPK2, RIPK3, RIPK4, CASP3, CASP7, CASP8, IKBKE, TRAF1, and BCL10. Acts as an important regulator of innate immune signaling via regulation of Toll-like receptors (TLRs), Nodlike receptors (NLRs) and RIG-I like receptors (RLRs), collectively referred to as pattern recognition receptors (PRRs). Protects cells from spontaneous formation of the ripoptosome, a large multi-protein complex that has the capability to kill cancer cells in a caspase-dependent and caspase- independent manner. Suppresses ripoptosome formation by ubiquitinating RIPK1 and CASP8. |
Cellular Location | Cytoplasm. Nucleus |
Tissue Location | Highly expressed in fetal lung, and kidney. In the adult, expression is mainly seen in lymphoid tissues, including spleen, thymus and peripheral blood lymphocytes |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
The protein encoded by this gene is a member of a family of proteins that inhibits apoptosis by binding to tumor necrosis factor receptor-associated factors TRAF1 and TRAF2, probably by interfering with activation of ICE-like proteases. The encoded protein inhibits apoptosis induced by serum deprivation but does not affect apoptosis resulting from exposure to menadione, a potent inducer of free radicals. The amino acid sequence predicts three baculovirus IAP repeat domains and a ring finger domain. Transcript variants encoding the same isoform have been identified. [provided by RefSeq].
References
Zane, L., et al. Virology 407(2):341-351(2010)
Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)
Kim, C.W., et al. Biochem. Biophys. Res. Commun. 400(1):46-52(2010)
Petersen, S.L., et al. Proc. Natl. Acad. Sci. U.S.A. 107(26):11936-11941(2010)
Friboulet, L., et al. BMC Cancer 10, 327 (2010) :
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.